NFKB1 and hepatocellular carcinoma: By elucidating these intricate immunosuppressive mechanisms, we can identify potential therapeutic targets to disrupt cytokine signaling, reprogram neutrophils, target the HBx-TLR4-NF-κB axis, and reverse EMT, thereby liberating the immune system and enhancing anti-tumor responses in HBV-HCC.